- Home
- UNCY
as 07-26-2024 4:00pm EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LOS ALTOS |
| Market Cap: | 17.2M | IPO Year: | 2021 |
| Target Price: | $5.63 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $1.82 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Unicycive Therapeutics Inc. News
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Unicycive Therapeutics Receives US Patent for Potential Acute Kidney Treatment
GlobeNewswire
10 days ago
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
GlobeNewswire
16 days ago
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
GlobeNewswire
17 days ago
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
MT Newswires
21 days ago
Unicycive Therapeutics Files Shelf Registration for Sale of Up to 50 Million Shares by Stockholders
GlobeNewswire
a month ago
Unicycive Therapeutics Joins Russell Microcap® Index
GlobeNewswire
a month ago
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
Simply Wall St.
a month ago
When Can We Expect A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY)?
Compare UNCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UNCY Unicycive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.